The Filing Desk

Editas Medicine vs Kymera Therapeutics

Editas Medicine EDIT · Kymera Therapeutics KYMR · Biotechnology

Editas Medicine reported revenue of $40 million in fiscal 2025, about the same as Kymera Therapeutics' $39 million in fiscal 2025. Editas Medicine's revenue grew 25.4% in its latest year, and Kymera Therapeutics' fell 16.7%. Editas Medicine had an operating margin of -394.9%, against -891.1% at Kymera Therapeutics. Free cash flow was −$166 million at Editas Medicine and −$234 million at Kymera Therapeutics.

Side by side

Editas MedicineKymera Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$40M$39M
Revenue growth25.4%−16.7%
Revenue growth a year, last 5 years−14.9%2.9%
Gross margin—0.0%
Operating margin−394.9%−891.1%
Net margin−395.0%−794.0%
Free cash flow−$166M−$234M
Free cash flow margin−409.3%−597.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count7.8%12.6%
Last close$2.17$127.57
P/E at the last close——
Insider trades, last 12 months—bought $172.5 million, sold $461.2 million
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Editas MedicineKymera Therapeutics
Operating margin
Percent of revenue
Editas MedicineKymera Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Editas MedicineKymera Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Editas Medicine and Kymera Therapeutics pages.